Matthew L. Kaplan - Net Worth and Insider Trading

Matthew L. Kaplan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew L. Kaplan owns 1 companies in total, including Nuvectis Pharma Inc (NVCT) .

Click here to see the complete history of Matthew L. Kaplan’s form 4 insider trades.

Insider Ownership Summary of Matthew L. Kaplan

Ticker	Comapny	Transaction Date	Type of Owner
NVCT	Nuvectis Pharma Inc	2022-02-08	director

Matthew L. Kaplan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Matthew L. Kaplan Ownership Network

Ownership Network List of Matthew L. Kaplan

No Data

Ownership Network Relation of Matthew L. Kaplan

Matthew L. Kaplan Owned Company Details

What does Nuvectis Pharma Inc do?

Who are the key executives at Nuvectis Pharma Inc?

Matthew L. Kaplan is the director of Nuvectis Pharma Inc. Other key executives at Nuvectis Pharma Inc include Vice President & Finance Michael J. Carson , director & Chairman & CEO Ron Bentsur , and Chief Development Officer Shay Shemesh .

Nuvectis Pharma Inc (NVCT) Insider Trades Summary

Over the past 18 months, Matthew L. Kaplan made no insider transaction in Nuvectis Pharma Inc (NVCT). Other recent insider transactions involving Nuvectis Pharma Inc (NVCT) include a net purchase of 18,095 shares made by Ron Bentsur , a net purchase of 202,124 shares made by Marlio Charles Mosseri , and a net sale of 2,755 shares made by Michael J. Carson .

In summary, during the past 3 months, insiders sold 2,755 shares of Nuvectis Pharma Inc (NVCT) in total and bought 0 shares, with a net sale of 2,755 shares. During the past 18 months, 2,755 shares of Nuvectis Pharma Inc (NVCT) were sold and 221,832 shares were bought by its insiders, resulting in a net purchase of 219,077 shares.

Nuvectis Pharma Inc (NVCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nuvectis Pharma Inc Insider Transactions

No Available Data

Matthew L. Kaplan Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew L. Kaplan. You might contact Matthew L. Kaplan via mailing address: C/o Nuvectis Pharma, Inc., 1 Bridge Plaza, Suite 275, Fort Lee Nj 07024.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.